La vendita allo scoperto per Miroku Jyoho Service dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Miroku Jyoho Service. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Miroku Jyoho Service (OTC:RKICF) Azioni, Report sulle vendite allo scoperto

Miroku Jyoho Service Co Ltd offers systems, solutions, and services to accounting firms and their client companies, small and mid-sized companies and data-compatible financial accounting systems. The firm's products include software applications, hardware, and supplies. Its services include tax service, account processing service, management guidance service, IT support and provision of management information services and installation and software and hardware support services etc.

MIROKU JYOHO SERVICE CO by MIROKU JYOHO SERVICE CO LTD.

Miroku Jyoho Service Co Ltd

MINISO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) reported quarterly earnings of RMB2.20 per share which missed the analyst consensus estimate of RMB2.21 by 0.45 percent. This is a 7.84 percent increase over earnings of RMB2.04 per share from the same period last year. The company reported quarterly sales of RMB4.522 billion which missed the analyst consensus estimate of RMB4.609 billion by 1.88 percent. This is a 19.28 percent increase over sales of RMB3.791 billion the same period last year.

Earnings

Earnings Misses

News

MNSO

MINISO Group Holding Q1 2025 Adj. EPS RMB2.20 Misses RMB2.21 Estimate, Sales RMB4.522B Miss RMB4.609B Estimate

GPRK

GeoPark Inks Binding Agreement To Acquire Repsol's 45% Stake In CPO-9 And 25% In Llanos Norte Oil Projects In Colombia

Through this acquisition, we will expand our maintenance business in Norway and further strengthen our business foundation by promoting a strategy aimed at increasing our elevator maintenance stock in the European market, where we anticipate continued growth in demand for maintenance and renewal.

MIELY

Mitsubishi Electric Enhances European Elevator And Escalator Business Through Acquisition Of ALT Heis

<h3>Companies Reporting Before The Bell</h3>
• MINISO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $659.09 million. 
<h3>Companies Reporting After The Bell</h3>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Scheduled For November 29, 2024

<ul>
<li>Wearable robot 'X-ble Shoulder' to boost industrial efficiency and reduce musculoskeletal injuries</li>
<li>Designed to assist overhead work by enhancing upper arm muscle strength, expected to find use in various industries</li>
<li>The strong yet lightweight X-ble Shoulder enhances worker comfort by reducing shoulder load by 60% and muscle activity by 30%</li>
<li>Hyundai Motor and Kia's Robotics LAB announced commercialization plan for X-ble Shoulder, expected to begin deliveries in first half of 2025</li>
</ul>

HYMTF

Reported Wednesday, Hyundai And Kia To Debut 'X-ble Shoulder' In 2025, Cutting Muscle Activity And Enhancing Worker Comfort For Overhead Tasks

EVTV

Reported Wednesday, Envirotech Vehicles Delivers Electric Vans To FedEx Partners, Promising Cost Savings And Zero Emissions

Macro Economic Events

Econ #s

Economics

France Harmonised Index of Consumer Prices (MoM) Preliminary For November -0.1% Vs. 0.0% Est.; 0.3% Prior

France Gross Domestic Product (QoQ) For Q3 0.4% Vs. 0.4% Est.; 0.2% Prior

France Gross Domestic Product (YoY) For Q3 1.2% Vs. 1.3% Est.; 1.0% Prior

France Consumer Price Index (MoM) Preliminary For -0.1% Vs. 0.0% Est.; 0.2% Prior

France Consumer Spending (MoM) For September -0.4% Vs. -0.1% Est.; 0.1% Prior

Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has introduced a major enhancement to its <a href="https://www.benzinga.com/topic/optimus">humanoid robot, Optimus</a>, featuring new hands.
What Happened: This announcement aligns with Neuralink&#8216;s recent FDA approval for its CONVOY Study. This trial will let Neuralink test its Brain-to-Computer (BCI) implant with assistive robotic arms – such as those of the Optimus bot.
This development follows Neuralink&#8217;s announcement of FDA approval for its CONVOY study, which will test the Brain-to-Computer-interface (BCI) N1 Implant with assistive robotic arms.
During a Neuralink update in July, Musk suggested that Optimus limbs could potentially work alongside the N1 implant. Neuralink also plans to allow participants to enroll in both the CONVOY and PRIME studies, the latter having already enabled two patients to control devices with their minds.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We're excited to announce the approval and launch of a new feasibility trial to extend BCI control using the N1 Implant to an investigational assistive robotic arm. This is an important first step towards restoring not only digital freedom, but also physical freedom. More info…
&mdash; Neuralink (@neuralink) <a href="https://twitter.com/neuralink/status/1861107594645119006?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The latest update from Tesla Optimus humorously stated, &#8220;Got&nbsp;a new hand for Black&nbsp;Friday,&#8221; showcasing the robot&#8217;s capability to catch&nbsp;a tennis ball with its&nbsp;upgraded hand.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Got a new hand for Black Friday <a href="https://t.co/x3gQrsbYAQ">pic.twitter.com/x3gQrsbYAQ</a>
&mdash; Tesla Optimus (@Tesla_Optimus) <a href="https://twitter.com/Tesla_Optimus/status/1862116407594377698?ref_src=twsrc%5Etfw">November 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In May,&nbsp;CEO Elon Musk&nbsp;indicated plans to enhance Optimus&#8217; hands to achieve 22 degrees of freedom, nearing the 27 degrees found in human hands.
See Also: <a href="https://www.benzinga.com/tech/24/11/42230503/tesla-cybercab-spotted-testing-in-giga-texas-facility">Tesla Cybercab Spotted Testing In Giga Texas Facility</a>
Why It Matters: The unveiling of the new hand upgrade for Tesla&#8217;s Optimus robot comes at a time when the company is making strides in autonomous navigation and interaction capabilities.
In October, Tesla showcased Optimus&#8217; ability to autonomously navigate a factory, avoid obstacles, and <a href="https://www.benzinga.com/news/24/10/41376564/tesla-showcases-optimus-autonomous-navigation-charging-abilities-after-admitting-they-were-human-ass">interact with humans</a> by handing over snacks and drinks upon request.
Moreover, Musk&nbsp;recently <a href="https://www.benzinga.com/tech/24/11/41834327/elon-musk-reveals-toughest-part-of-building-teslas-humanoid-robot-improving-the-design-of-optimus-for-ease-of-manufacturing">acknowledged the challenges</a> in refining Optimus&#8217; design for easier manufacturing and establishing a complex supply chain for mass production. Despite these hurdles, Musk remains optimistic about the long-term economic potential of humanoid robots driven by artificial general intelligence.
In a related development, <a href="https://www.benzinga.com/24/11/42159490/elon-musks-tesla-hunts-top-talent-to-develop-software-for-robotaxi-optimus-robot-teleoperation-2">Tesla is actively seeking top talent</a> to enhance software for the teleoperation of its robotaxis and Optimus robots. This initiative aims to develop low-latency, reliable data streaming solutions for real-world applications.
Price Action: Tesla stock closed at $332.89 on Wednesday, down 1.6% for the day. In after-hours trading, the stock increased slightly by 0.5%. Year to date, Tesla's stock has gained 34%, according to&nbsp;<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Analysts have a consensus rating of "Neutral" on the Tesla stock, according to Benzinga Pro data. The highest price target is $400, while the consensus price target is 232.20, implying a 30% downside.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42183055/elon-musk-slams-californias-proposal-to-shut-tesla-evs-out-of-consumer-rebates-in-state-this-is-insane?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Slams California&#8217;s Proposal To Shut Tesla EVs Out Of Consumer Rebates In State: &#8216;This Is Insane'</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Tesla

Tech

TSLA

Tesla's Optimus Bot Gets New Hands As Neuralink's FDA-Approved BCI Trials Begin

Major U.S. indices have advanced between 18% to 27% year-to-date. The S&amp;P 500 Index scaled its 52nd record high this year on Tuesday, Nov. 26. Bulls and Bears are locking horns as S&amp;P 500 is on track to deliver 20% plus year-to-date gains for the second time.
What Happened: Markets have been under pressure only once in the month of December over the last 95 years, according to the data highlighted by Ryan Detrick, chief market strategist at Carson Group LLC.
Thanksgiving falls on the fourth Thursday of November every year, addressing the next month of December, Detrick shared the data and said &#8220;Something to be thankful for?&#8221;, in an X (formerly Twitter). The data from 1928 to 2023 showed that September has been the worst 13 times while April is the worst month this year with a 4% drop.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Something to be thankful for? December has been the worst month of the year for stocks only once going back 95 years (2018 and the Fed policy mistake). Worst month this year has been the 4% drop in April. <a href="https://t.co/2ThL3DwD7x">pic.twitter.com/2ThL3DwD7x</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1862188406505185730?ref_src=twsrc%5Etfw">November 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Also read: <a href="http://GOP Megadonor Ken Griffin Slashes Citadel's Palantir Stake By 91%, Bets Big On Nvidia As Jensen Huang-Led Company Rises Over 180% In 2024">GOP Megadonor Ken Griffin Slashes Citadel&#8217;s Palantir Stake By 91%, Bets Big On Nvidia As Jensen Huang-Led Company Rises Over 180% In 2024</a>
On the other hand, David Cox, CMT, CFA, portfolio manager at Raymond James Ltd., in an X Post highlighted the likelihood of an upcoming to the investors, saying &#8220;If you want to sidestep a decline, watch the trend…&#8221;
The 13/34-week Exponential Moving Average signals a bullish market trend when the 13-week EMA line is above the 34-week EMA line and a bullish crossover results in a market correction. Predicting an upcoming crossover through his chart Cox said that &#8220;there will be another red circle some day&#8221;, The red circle in his chart represents a bullish crossover.
According to a <a href="https://www.cmgwealth.com/ri/how-i-think-about-the-13-34-week-exponential-moving-average/">note by CMGWealth</a>, the 13/34-week EMA analysis is a &#8220;simple, tactical trend indicator that has historically captured the cyclical bull and bear market trends.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">again, look at how much easier we can make it on ourselves&#8230; time frame matters, if you want to sidestep a decline, watch the trend&#8230; look at these 13/34-week EMA <a href="https://twitter.com/hashtag/bearish?src=hash&amp;ref_src=twsrc%5Etfw">#bearish</a> crossovers&#8230; they help you remove emotion, and stay focused&#8230; there will be another red circle some day <a href="https://t.co/kpAXx8F5jX">pic.twitter.com/kpAXx8F5jX</a>
&mdash; David Cox, CMT, CFA (@DavidCoxRJ) <a href="https://twitter.com/DavidCoxRJ/status/1861758050215891069?ref_src=twsrc%5Etfw">November 27, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Markets have been trading higher than their pre-election levels and the expectations of a further 25 basis point rate cut in December rose to just 66.3%, according to <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">CME Group&#8217;s FedWatch tool</a>. This indicates a further upside in the stock markets.
The S&amp;P 500 index has risen 26.48% year-to-date to basis. Whereas, the Nasdaq 100, Dow Jones, and Russell 200 Index have returned 25.39%, 18.58%, and 20.54%, respectively. The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up by 26.7% and the Invesco QQQ ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NYSE">QQQ</a>) advanced by 23.39%, according to Benzinga Pro data.
Read next: <a href="https://www.benzinga.com/general/market-summary/24/11/42206673/trumps-running-mate-vice-president-pick-and-venture-capitalist-jd-vance-holds-etfs-bitcoin-and-more-here-is-a-look-at-his-portfolio" target="_blank" rel="noreferrer noopener">JD Vance&#8217;s Investment Playbook Has Bitcoin And ETFs: Here&#8217;s What Else The VP-Elect Is Betting On</a>

Equities

Markets

Wall Street's December Surprise: What Investors Need to Know Now

BIIB

ESAIY

Reported Wednesday, Eisai and Biogen Introduce LEQEMBI In South Korea To Combat Alzheimer's And Mild Cognitive Impairment

Reported Wednesday, KKR And Weave Living Strengthen Partnership With $3,000+ Unit Residential Program In Japan

ZLAB

Reported Wednesday, Zai Lab Announces AUGTYRO Inclusion For ROS1+ NSCLC In China's Updated National Reimbursement Drug List

This collaboration aims to provide scalable solutions, accelerate time-to-market, and deliver innovative advancements. It will leverage Tech Mahindra's specialized talent pool and advanced labs, focusing on technologies expected to drive the future of connected devices, additive manufacturing, connected vehicles, and augmented and virtual reality. The center marks a significant milestone for USI as it expands its engineering capabilities to India, providing a strong foundation for enhancing device software development, hardware design, and testing. USI aims to&nbsp;leverage&nbsp;Tech Mahindra's expertise, particularly the need for scalability and flexibility, faster product launches, and access to specialized skills and facilities.&nbsp;

Reported Thursday, ASE Technology Subsidiary USI Partners With Tech Mahindra To Establish Engineering Offshore Development Center In Bengaluru

ORPATHYS&#xAE;&nbsp;is an oral, potent, and highly selective MET tyrosine kinase inhibitor ("TKI"). It received conditional approval in China in June 2021 for the treatment of certain patients with non-small cell lung cancer ("NSCLC") with MET exon 14 skipping alterations. More than a third of the world's lung cancer patients are in China and, among those with NSCLC globally, approximately 2-3% have tumors with MET exon 14 skipping alterations.

Reported Thursday, HUTCHMED Confirms ORPATHYS (Savolitinib) Retains Spot On China's National Reimbursement Drug List

<ul>
<li>New Barcelona site to help drive global expansion of QIAstat-Dx as QIAGEN expands local presence with multi-year investment</li>
<li>Site in Esplugues de Llobregat to serve as an innovation hub for QIAstat-Dx, supporting the development of infectious disease tests and precision medicine applications</li>
</ul>

QGEN

Reported Thursday, QIAGEN Boosts QIAstat-Dx With New Barcelona Hub For Infectious Disease And Precision Medicine Testing

<ul>
<li>Only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA, NMPA and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC)</li>
<li>Combination of Toripalimab and standard of care chemotherapy has shown a 48% reduction in risk of progression or death</li>
<li>Launched in India in the same year as its launch in the U.S., making India the third country in the world to receive access to this New Biological Entity (NBE)</li>
</ul>

Comments

Miroku Jyoho Service

Vendite allo scoperto

Miroku Jyoho Service (OTC:RKICF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO